Archive | SAN MARINO, Calif.

Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

By Send2Press Newswire on February 28, 2011 in California, Drugs and Pharmaceuticals, Medical, Pharma, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents

By Send2Press Newswire on July 6, 2010 in California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two […]

Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)

By Send2Press Newswire on June 1, 2010 in California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. […]

Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)

By Send2Press Newswire on May 24, 2010 in California, Devices and Research, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical study entitled ‘Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New […]

Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)

By Send2Press Newswire on May 24, 2010 in California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the […]

Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy

By Send2Press Newswire on May 4, 2010 in California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector […]

SERVICES

Navigation